Physician profile
Alva B Weir
NPI 1851413140
$1,641.58
in general payments reported to CMS, 2019-2025
10 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $73.49 · 2021: $213 · 2023: $141 · 2024: $120 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $882 · Education: $200 · Food and Beverage: $95.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $882.09 |
| Education | $199.90 |
| Food and Beverage | $95.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $933.07 | 2019-2025 | |
| Seagen INC. | $512.60 | 2019-2024 | |
| Novocure INC. | $73.49 | 2020 | |
| Celgene Corporation | $40.63 | 2023 | Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $25.12 | 2019-2021 | |
| Genzyme Corporation | $24.65 | 2019 | |
| Lilly USA, LLC | $20.21 | 2024 | Verzenio, Jaypirca |
| Amgen INC. | $11.81 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alva Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.